| Methods |
Single centre, double‐blind, placebo‐controlled
Randomisation using serially numbered sealed envelopes; the code was held by pharmacy
Stratified by delay of symptoms to randomisation, age and severity of symptoms
ITT analysis |
| Participants |
Sweden
26 participants: T: 13, C: 13
Mean age: 74 years, T: 76.3 years, C: 71.5 years
14 males, 12 females
100% CT
Enrolment within 36 hours |
| Interventions |
T: loading dose of 4 mmol magnesium sulfate iv over 10 minutes followed by continuous iv of 4 mmol magnesium sulfate during the following 8 hours, then after iv infusion one 250 mg magnesium hydroxide po, then 250 mg magnesium hydroxide po 8‐hourly for following 5 days
C: equal volumes of isotonic saline and placebo pills
Rx: 5 days |
| Outcomes |
Scandinavian Stroke Study Group (neurological score) at baseline, day 6 and 6 months
Method of BP measurement not known |
| Notes |
Ex: SBP < 110 mmHg on admission, AV‐block II‐III, major renal impairment, respiratory insufficiency, pre‐existing functional impairment confusing proper evaluation of therapeutic effects, concomitant severe disorders, and ongoing anticoagulant treatment, plasma creatinine > 200 umol/l and EKG showing AV‐block II‐III |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Low risk |
Randomisation using serially numbered sealed envelopes |
| Allocation concealment? |
Low risk |
Randomisation code were held by pharmacy |
| Blinding? |
Low risk |
Probably done |
| Completeness of follow‐up |
Unclear risk |
Unclear from publication |
